Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience
This study was done to assess the overall response rate of imatinib mesylate in local patients with chronic myeloid leukaemia. A total of 69 patients were recruited with male/female ratio of 7:3. Of the 69 patients; 35% were in the chronic phase, 41% were in the accelerated phase, 17% were in blast...
Main Authors: | Bee, P.C., Gan, G.G., Teh, A., Haris, A.R. |
---|---|
Format: | Article |
Published: |
Malaysian Medical Association
2006
|
Subjects: |
Similar Items
-
An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
by: Bee, P.C., et al.
Published: (2012) -
Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate
by: Nadarajan, V.S., et al.
Published: (2011) -
Detection of PDGFRA mutations at exons 12 and 18 among chronic myeloid leukemia patients treated with imatinib mesylate
by: Razali, Ruzi Hamimi
Published: (2015) -
Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients
by: Elias, Marjanu Hikmah
Published: (2015) -
Identification of unbalanced genomic aberrations by array cgh in chronic myeloid leukemia patients with suboptimal response to imatinib treatment
by: Phan, C.L., et al.
Published: (2010)